We found that VIM-CD44, COL1A1-CD44, B2M-CD3D, and the interaction between the ligand COL1A1/COL1A2/COL3A1 and the ITGB1 receptor showed significant benefits in the tumor microenvironment of both patients. The gene discussed is B2M; the disease is neoplasm.